Epigenetic Regulation of IFI44L Expression in Monocytes Affects the Functions of Monocyte-Derived Dendritic Cells in Systemic Lupus Erythematosus

Table 1

Demographics and medications of all patients in this study.

Patient no.	Gender	Age (years)	Disease duration	SLEDAI	Treatment regimen
1	F	44	1 year	12	None
2	F	36	2 years	6	Prednisone 20 mg/d
3	F	34	9 months	10	Prednisone 30 mg/d, hydroxychloroquine
4	F	41	8 years	2	Prednisone 12.5 mg/d
5	F	26	5 years	10	Prednisone 30 mg/d
6	F	33	1 year	41	Prednisone 30 mg/d
7	F	53	10 years	8	Prednisone 15 mg/d
8	F	32	17 years	13	Prednisone 30 mg/d
9	F	32	5 years	18	Prednisone 35 mg/d, hydroxychloroquine, cyclophosphamide
10	F	36	3 years	14	Prednisone 10 mg/d, hydroxychloroquine
11	F	32	3 months	14	Prednisone 55 mg/d
12	F	27	3 years	4	Prednisone 10 mg/d
13	F	36	4 years	12	Prednisone 50 mg/d, hydroxychloroquine
14	F	50	10 years	15	None
15	F	50	1 year	12	Prednisone 10 mg/d
16	F	37	6 years	17	Prednisone 15 mg/d
17	F	26	4 months	20	Prednisone 20 mg/d, hydroxychloroquine
18	M	23	1 month	11	None
19	M	36	1 year	30	None
20	M	18	4 years	24	Methylprednisolone 28 mg/d

SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; F: female; M: male; none: no treatment with drugs.